ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. (scientific article published on 5 December 2015)

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

Q33419897

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Q33651005

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Q34221860

The resurgence of platinum-based cancer chemotherapy

Q34649255

Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity

Q34715440

ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA

Q35176008

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

Q35550255

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest

Q36586535

First total synthesis of protoapigenone and its analogues as potent cytotoxic agents

Q36982937

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage

Q37342444

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Q37638784

Molecular mechanisms of cisplatin resistance

Q37926477

Urothelial carcinoma of the bladder: definition, treatment and future efforts

Q37944437

The DNA damage response and cancer therapy

Q37977004

Molecular mechanisms of cisplatin resistance in bladder cancer.

Q37982453

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Q38037329

Targeting ATR in DNA damage response and cancer therapeutics.

Q38098757

Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG).

Q38247907

A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells

Q38934163

Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance

Q38966196

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

Q38983310

A novel compound RY10-4 induces apoptosis and inhibits invasion via inhibiting STAT3 through ERK-, p38-dependent pathways in human lung adenocarcinoma A549 cells

Q39050063

Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo

Q39359058

Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.

Q39530481

ATR mediates cisplatin resistance in a p53 genotype-specific manner

Q39604095

A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species

Q39604402

Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.

Q40002991

New cytotoxic flavonoids from Thelypteris torresiana

Q40365308

Pathology and staging of urothelial tumors of the kidney and ureter

Q40854016

Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.

Q43084851

Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors

Q43823457

P433

issue

P407